Reports suggest that SARS-CoV-2 virus has the ability to directly infect human blood vessel and kidney organoids. The use of clinical-grade recombinant human ACE2 (rhACE2) can reduce SARS-CoV-2 infection in cells and multiple human organoid models. Furthermore, the same study has also suggested that the application of soluble human ACE2 in early stages of infection can block SARS-CoV-2 entry into host cells. Currently, there is one clinical trial sponsored by Apeiron Biologics in phase-2 testing the use of rhACE2 for the treatment of COVID-19 patients.
Excelra's open-access COVID-19 Drug Repurposing Database is a synoptic compilation of ‘Approved’ small molecules and biologics, which can rapidly enter either Phase 2 or 3, or may even be used directly in clinical settings against COVID-19. The database additionally includes information on promising drug candidates that are in various clinical, pre-clinical and experimental stages of drug discovery and development.
Supported with referenced literature, we provide mechanistic insights into SARS-CoV-2 biology and disease pathogenesis. We hope that these drug repositioning approaches can help the global biotech and pharma community develop treatments to combat COVID-19.